The first positron emission tomography (PET) tracers of tau pathology were developed almost a decade ago.1 These tracers have advanced our understanding of the role of tau pathology in aging and Alzheimer’s disease.2–5 However, several questions remain, including the spatial progression of the disease across the whole brain. The gene discussed is MAPT; the disease is Alzheimer disease.